AbbVie said it expects acquired IPR&D and milestones expense of $1.6 billion on a pre-tax basis to be included in GAAP and adjusted non-GAAP results for Q4 2024, representing an unfavorable impact of $0.88 to diluted earnings per share, and results have not been finalized.

1. 01

   AbbVie said it expects acquired IPR&D and milestones expense of $1.6 billion on a pre-tax basis to be included in GAAP and adjusted non-GAAP results for Q4 2024, representing an unfavorable impact of $0.88 to diluted earnings per share, and results have not been finalized.

2. 02

   The company presented acquired IPR&D and milestones expense of $1,574 million and an impact on earnings per share of $(0.88) for Q4 2024 in the attached table (in millions, except per share data), with the prior guidance excluding such expense for Q4.

3. 03

   AbbVie said its adjusted diluted earnings per share guidance range for Q4 2024, including the impact of acquired IPR&D and milestones expense for Q4, is $2.06 to $2.10, compared with prior guidance of $2.94 to $2.98 excluding such expense (in millions, except per share data).

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.